In This Article
If you've been getting your GLP-1 medication from a compounding pharmacy, the regulatory landscape has shifted significantly. The FDA has moved to restrict compounded semaglutide and tirzepatide — and in early 2026, enforcement reached a new level.
This might feel concerning, but the goal is patient safety — and the good news is there are now more affordable FDA-approved options than ever. Here's what you need to know.
The Regulatory Timeline
2023–2024: The Shortage Era. When demand far exceeded supply, the FDA listed these drugs as "in shortage," opening a legal pathway for compounding pharmacies. Compounded GLP-1s surged — often $100–$300/month versus $1,000+ for brand name.
Late 2024–Mid 2025: Shortages resolved. As manufacturers caught up, the FDA removed both tirzepatide and semaglutide from its shortage list. The legal authorization for compounding began to expire.
September 2025: Warning letters. Dozens of warnings for misleading marketing — claims that compounded drugs were "generic" or "equivalent."
February 2026 Escalation
In February 2026, the FDA announced broad enforcement action against non-FDA-approved GLP-1 drugs. HHS also referred at least one major telehealth company to the DOJ for potential violations.
Important distinction: The FDA did not ban all GLP-1 compounding. Patient-specific compounding with documented medical necessity remains a narrow legal pathway. What's targeted is mass-marketed, non-patient-specific compounding.
Is Compounded Semaglutide Still Legal?
The legal pathway is extremely narrow. If your provider is still offering compounded GLP-1s, ask: Is this patient-specific with documented medical necessity? Is the pharmacy state-licensed and sourcing from FDA-registered facilities? If you can't get clear answers, it's time to transition.
Patient Safety Concerns
The FDA's actions are driven by real safety issues: multiple recalls for quality control problems, fraudulent products with fake pharmacy labels, and hospitalizations from improper dosing and contamination.
This isn't just regulatory paperwork — it's about making sure the medication you're putting in your body is safe, pure, and dosed correctly. (For more context on what's real and what's overblown about GLP-1 safety, see our piece on weight loss medication myths.)
Your Options Going Forward
The transition away from compounding doesn't leave you without options:
Oral Wegovy: Launched January 2026 at $149–$299/month. No injections, no refrigeration. The most affordable FDA-approved GLP-1 available.
Manufacturer savings programs: As low as $25/month with commercial insurance.
Telehealth platforms: Multiple legitimate platforms now prescribe brand-name GLP-1s and help navigate insurance and savings.
For a complete breakdown of all the pricing options, see our GLP-1 cost guide.
Compare legitimate telehealth platforms that prescribe FDA-approved GLP-1 medications — with transparent pricing and licensed physicians.
Compare Top Providers →Silver lining: While the compounding crackdown closes one door, the arrival of oral Wegovy at $149/month, expanded insurance coverage, and manufacturer savings are opening others. The path to safe, affordable GLP-1 treatment is actually better in 2026 than ever.